FindTrial
Sign In

Tubarial Salivary glands : Radiation Dosimetry and sparing

Dosimetric and Feasibility study of Sparing of Tubarial Salivary Glands in Head and Neck Cancer patients treated with Definitive Radiotherapy, with or without Concurrent Chemotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2022/11/047451
Enrollment
45
Registered
2022-11-21
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C148- Malignant neoplasm of overlappingsites of lip, oral cavity and pharynx

Interventions

None listed

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. WHO PS 0,1 2. Non-Nasopharyngeal and Non PNS/Nasal cavity Head and Neck Cancers 3. Definitive Radiotherapy. 4. For prospective study- patients with no overlap of the planning target volume (PTV) with tubarial glands will be considered

Exclusion criteria

Exclusion criteria: 1. WHO PS >2 2. Nasopharyngeal tumors 3. PNS tumors 4. Post op HNC 5. Post NACT 6. Re RT 7. If Treating RPLN 8. Post pharyngeal wall tumors 9. Oropharyngeal tumors extending into Nasopharynx

Design outcomes

Primary

MeasureTime frame
1. Primary endpoint: Dosimetry of Tubarial glands 2. Secondary end point: Late Xerostomia, locoregional controlTimepoint: PSMA PETCET at baseline and after 6 months of treatment completion ( only of prospective participants )—

Secondary

MeasureTime frame
NATimepoint: NA—

Countries

India

Contacts

Public ContactDr Ranjan Subramani

Tata Memorial Hospital

ashwini.budrukkar@gmail.com0222417152

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026